Press Releases

Date	Title	Company
12-Dec-2022	Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH	Businesswire
12-Dec-2022	Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing	Legend Capital
12-Dec-2022	Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting	Businesswire
11-Dec-2022	Se aprueba el uso de QDENGA®▼ (vacuna tetravalente contra el dengue, de virus vivo atenuado) de Takeda en la Unión Europea	Businesswire
11-Dec-2022	MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022	MorphoSys AG
11-Dec-2022	Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022	Businesswire
11-Dec-2022	MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting	Businesswire
11-Dec-2022	Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting	Businesswire
11-Dec-2022	Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth	Businesswire
10-Dec-2022	Takeda présentera des données à l’occasion du 64e congrès annuel de la Société américaine d’hématologie, démontrant son engagement envers les patients atteints de cancers hématologiques et d’autres maladies du sang	Businesswire
10-Dec-2022	Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th ASH Annual Meeting	Businesswire
10-Dec-2022	MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022	MorphoSys AG
10-Dec-2022	MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting	Businesswire
10-Dec-2022	Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)	Businesswire
10-Dec-2022	Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022	Businesswire
10-Dec-2022	Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting	Businesswire
10-Dec-2022	Takeda apresenta dados no 64º Encontro Anual da Sociedade Americana de Hematologia (ASH), demonstrando compromisso com pacientes com cânceres hematológicos e outras doenças sanguíneas	Businesswire
10-Dec-2022	Takeda presentará datos en el 64.° Congreso Anual de la Sociedad Americana de Hematología (ASH), demostrando su compromiso con los pacientes con cánceres hematológicos y demás enfermedades de la sangre	Businesswire
10-Dec-2022	Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition	Businesswire
10-Dec-2022	Herbolea Biotech and Iberfar Announce Strategic Partnership and Commercial Relationship	Newswire